Profile data is unavailable for this security.
About the company
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.
- Revenue in CAD (TTM)0.00
- Net income in CAD-2.63m
- Incorporated2004
- Employees--
- LocationClaritas Pharmaceuticals Inc4040 Civic Center Drive, Suite 200SAN RAFAEL 94903United StatesUSA
- Phone+1 (416) 362-4441
- Fax+1 (403) 266-8647
- Websitehttps://claritaspharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zenith Capital Corp | 0.00 | -23.20m | 775.60k | -- | -- | -- | -- | -- | -0.1584 | -0.1584 | 0.00 | -0.1709 | 0.00 | -- | -- | -- | -339.76 | -- | -- | -- | -- | -- | -- | -- | -- | -9.97 | -- | -- | -- | -- | -68.27 | -- | -- | -- |
Well Told Company Inc | -100.00bn | -100.00bn | 781.42k | -- | -- | -- | -- | -- | -- | -- | -- | -0.0053 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.3492 | -- | 2.27 | -- | -- | -- | -- | -- | -- | -- |
Psybio Therapeutics Corp | 0.00 | -3.87m | 838.84k | 4.00 | -- | -- | -- | -- | -0.0332 | -0.0332 | 0.00 | -0.0182 | 0.00 | -- | -- | -- | -357.70 | -- | -- | -- | -- | -- | -- | -- | -- | -617.30 | -- | -- | -- | -- | 55.66 | -- | -- | -- |
Lumiera Health Inc | 595.14k | -2.37m | 848.71k | -- | -- | -- | -- | 1.43 | -0.0139 | -0.0139 | 0.0035 | -0.0137 | 0.5096 | 2.13 | 11.78 | -- | -202.92 | -- | -- | -- | 13.17 | -- | -398.18 | -- | 0.0395 | -2.10 | -- | -- | 46.91 | -- | -188.58 | -- | -- | -- |
NeutriSci International Inc | 59.98k | -552.46k | 892.12k | -- | -- | -- | -- | 14.87 | -0.0032 | -0.0032 | 0.0003 | -0.0051 | 0.2988 | 1.33 | 11.47 | -- | -275.23 | -288.65 | -- | -- | -43.90 | -7.95 | -921.07 | -1,046.33 | 0.0059 | -- | -- | -- | 465.89 | 24.82 | 50.98 | -- | -- | -- |
Hill Inc | 2.22m | -1.97m | 902.77k | -- | -- | 1.27 | -- | 0.4069 | -0.6076 | -0.6076 | 0.6822 | 0.2159 | 0.5046 | 129.23 | 4.56 | -- | -44.92 | -77.46 | -48.92 | -101.03 | 68.14 | 50.14 | -89.01 | -153.93 | 2.97 | -4.23 | 0.7881 | -- | -10.23 | 33.86 | 18.26 | -- | 16.21 | -- |
Claritas Pharmaceuticals Inc | 0.00 | -2.63m | 961.32k | -- | -- | -- | -- | -- | -0.0855 | -0.2047 | 0.00 | 0.1273 | 0.00 | -- | -- | -- | -17.49 | -33.39 | -51.79 | -39.16 | -- | -- | -- | -- | -- | 6.86 | 0.1409 | -- | -- | -- | 119.85 | -- | -- | -- |